慢性腎臟病：全球市場與技術

2025 年全球慢性腎臟病市場規模為 529 億美元，預計從 2025 年到 2030 年將以 9.3% 的年複合成長率成長，到 2030 年達到 826 億美元。

預計到 2025 年，北美慢性腎臟病市場規模將達到 246 億美元，從 2025 年到 2030 年，年複合成長率將達到 8.8%，到 2030 年將達到 375 億美元。

2025年亞太地區慢性腎臟病市場價值為91億美元，預計從2025年到2030年將以11.1%的年複合成長率成長，到2030年達到154億美元。

調查範圍

全球慢性腎臟病)市場按技術類型、藥物和終端用戶進行細分。從技術角度來看，該市場分為診斷、治療和腎臟替代療法解決方案。診斷技術包括基於生物標記的檢測、影像技術、就地檢驗以及基因組和蛋白質組學篩檢，這些技術能夠實現早期診斷和持續的疾病評估。治療技術包括傳統藥物療法、創新細胞和基因療法以及旨在延緩疾病進展和改善患者預後的先進藥物遞送系統。血液透析、腹膜透析和生物工程人工腎臟等腎臟替代療法技術主要用於慢性腎臟病(CKD) 的晚期和末期治療。

就藥品而言，市場細分是基於慢性腎臟病 (CKD) 的分期（1-5 期）以及透析和移植後護理所用藥物。這種細分反映了疾病嚴重程度和治療環境相關的治療需求差異。根據最終用戶，市場細分為醫院、診所和家庭或機構透析。醫院和診所憑藉其全面的護理能力佔據最大市場佔有率，而居家照護領域則因患者偏好增加、便利性提升以及透析技術的進步而快速成長。市場估算與預測以 2024 年為基準年，2025 年為估算年，預測資料涵蓋 2026 年至 2030 年。

本報告內容

• 57個數據表和43個補充表
• 對全球慢性腎臟病（CKD）及相關技術市場進行詳細分析。
• 全球趨勢分析，包括 2022 年至 2024 年的歷史銷售數據、2025 年的預測數據以及到 2030 年的年複合成長率預測。
• 目前市場規模估算和銷售預測，以及按產品類型、應用、最終用戶和地區分類的市場佔有率分析。
• 有關市場動態、技術進步、法規、前景、贖回慣例和宏觀經濟變數的影響的事實和數據。
• 基於波特五力模型和全球供應鏈分析的見解。
• 提供有關慢性腎臟病現狀的信息，重點關注生物標記、診斷方法以及支持有效疾病管理的行動應用程式。
• 對 CKD 合併症（如糖尿病和代謝性疾病）進行調查，並發現了治療方法和診斷方法的重要成果。
• 審查主要專利的授權和公佈狀態
• 產業結構分析（包括各公司的市場佔有率和全球排名、產品佈局、策略舉措、併購活動和創業融資前景）
• 概述永續發展趨勢和ESG進展。重點關注消費者意識以及大型企業對ESG風險的評估和實施。
• 業界領導企業的公司簡介，包括費森尤斯醫療股份公司、百特公司、貝朗公司、尼普洛公司和美敦力公司。

目錄

第1章：執行摘要

• 市場展望
• 本報告範圍
• 市場概況
• 市場動態與成長要素
• 新興技術
• 基於細分市場的分析
• 區域分析
• 結論

第2章 市場概覽

• 概述
• 宏觀經濟因素分析
• 醫療保健支出增加以及醫療保健領域對慢性病的關注
• 人口老化與人口結構變化
• 與經濟發展、都市化和生活方式相關的健康風險
• 增加對醫療基礎設施的投資，並擴大醫療服務的覆蓋範圍。
• 美國關稅措施和全球貿易趨勢的影響
• 波特五力分析
• 新進入者的潛力
• 供應商的議價能力
• 買方的議價能力
• 替代品的威脅
• 產業競爭

第3章 市場動態

• 概述
• 市場促進因素
• 在全球範圍內，糖尿病和高血壓等慢性疾病的盛行率不斷上升。
• 從早期慢性腎臟病（CKD）發展到末期腎功能衰竭（ESRD）的速度。
• 透析中心和檢測機構數量增加
• 市場限制因素
• 前期投資和治療費用高昂，且保險報銷有限。
• 嚴格的規章制度和核准要求
• 認知度低和診斷延遲
• 市場機遇
• 增加對再生醫學和生物療法的投資
• 產業領軍企業正在擴大研發投入。
• 主要公司的研究與發展計劃

第4章 監管情勢

• 概述
• 美國監管情勢
• 歐洲的監管情勢
• 亞太地區的監管情勢
• 日本
• 中國
• 印度
• 世界其他地區的監管趨勢

第5章：新興技術與專利分析

• 概述
• 新趨勢和技術
• 先進的診斷技術
• 新型治療方法和生物製藥
• 穿戴式和植入式腎臟裝置
• 人工智慧、機器學習和數位技術
• 再生醫學及組織工程
• 專利分析

第6章 市場區隔分析

• 細分市場
• 按技術分類的市場細分
• 重點
• 診斷技術
• 治療技術
• 腎臟替代療法技術
• 按藥品分類的市場細分
• 重點
• 按最終用戶分類的市場細分
• 重點
• 按地區分類
• 按地區分類的市場細分
• 重點
• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 南美洲

第7章 競爭訊息

• 競爭分析
• 戰略分析
• 投資環境

第8章慢性腎臟病市場的永續性：ESG觀點

• 概述
• 人工智慧在慢性腎臟病產業的永續發展趨勢和舉措
• ESG風險評估
• BCC Force 的研究結果

第9章附錄

• 調查方法
• 簡稱
• 參考
• 公司簡介
• ABBVIE INC.
• AMGEN INC.
• ASTELLAS PHARMA INC.
• BAXTER
• BAYER AG
• B. BRAUN SE
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• FRESENIUS MEDICAL CARE AG
• JOHNSON & JOHNSON
• LILLY USA LLC
• NOVARTIS AG
• PFIZER INC.
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• TORAY INDUSTRIES INC.
• 新興創業公司/市場顛覆者

The global market for chronic kidney disease was valued at $52.9 billion in 2025 and is estimated to reach $82.6 billion by 2030, at a compound annual growth rate (CAGR) of 9.3% from 2025 through 2030.

The North American market for chronic kidney disease was valued at $24.6 billion in 2025 and is estimated to reach $37.5 billion by 2030, at a CAGR of 8.8% from 2025 through 2030.

The Asia-Pacific market for chronic kidney disease was valued at $9.1 billion in 2025 and is estimated to reach $15.4 billion by 2030, at a CAGR of 11.1% from 2025 through 2030.

Report Scope

The global market for chronic kidney disease is segmented by technology type, pharmaceutical drugs, and end users. From a technological perspective, the market is divided into diagnostic, therapeutic, and renal replacement solutions. Diagnostic technologies encompass biomarker-driven assays, imaging techniques, point-of-care testing, and genomic and proteomic screening, which facilitate early diagnosis and ongoing disease assessment. Therapeutic technologies encompass conventional drug treatments, innovative cell- and gene-based therapies, and advanced drug delivery systems, designed to slow disease progression and enhance patient outcomes. Renal replacement technologies, such as hemodialysis, peritoneal dialysis, and bioengineered artificial kidneys, are predominantly utilized in late-stage and end-stage CKD management.

In terms of pharmaceutical drugs, the market is segmented by CKD stage (Stage 1-5) and by medications used for dialysis and post-transplant care. This segmentation reflects the varying therapeutic requirements associated with disease severity and treatment settings. Based on end users, the market is classified into hospitals, clinics, and home-based or in-house dialysis settings. Hospitals and clinics account for the largest share due to comprehensive care capabilities, but the home care segment is experiencing rapid growth driven by increased patient preference, convenience, and advances in dialysis technologies. For market estimates, data has been provided for 2024 as the base year, 2025 as the estimated year, and with forecasts for 2026 through 2030.

Report Includes

• 57 data tables and 43 additional tables
• In-depth analysis of the global markets for chronic kidney diseases (CKD) and related technologies
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue forecasts, along with a corresponding market share analysis by product type, application, end-user and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, prospects, reimbursement practices, and the impact of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Information on current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods and mobile apps that support effective disease state management
• Key insight into research on CKD comorbidities such as diabetes and metabolic disease, as well as treatment methods and diagnostics
• Review of key granted and published patents
• Analysis of the industry structure, including companies' shares and global rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Fresenius Medical Care AG, Baxter, B. Braun SE, NIPRO, and Medtronic

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Growth in Healthcare Spending and Focus on Chronic Conditions
• Aging Populations and Shifting Demographic Patterns
• Economic Development, Urbanization, and Lifestyle-Related Health Risks
• Investment in Healthcare Infrastructure and Broader Access to Care
• Impact of U.S. Tariffs and Global Trade Dynamics
• Porter's Five Forces Analysis
• Potential for New Entrants to the Market
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitutes
• Competition in the Industry

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Growing Prevalence of Chronic Diseases Such as Diabetes and Hypertension Globally
• Progression Rate from Early-Stage CKD to End-Stage Renal Disease (ESRD)
• Increased Number of Dialysis Centers and Laboratories
• Market Restraints
• High Capital and High Cost of Treatment and Limited Reimbursement
• Stringent Regulatory and Approval Requirements
• Low Awareness and Late Diagnosis
• Market Opportunities
• Growing Investment in Regenerative Medicine and Biologic Therapies
• Expanding Research and Development Efforts by Industry Leaders
• Research and Development Initiatives from Key Companies

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Asia-Pacific
• Japan
• China
• India
• Regulatory Scenario in the Rest of the World

Chapter 5 Emerging Technologies and Patent Analysis

• Overview
• Emerging Trends/Technologies
• Advanced Diagnostic Technologies
• Novel Therapeutics and Biologics
• Wearable and Implantable Renal Devices
• Artificial Intelligence, Machine Learning, and Digital Health
• Regenerative Medicine and Tissue Engineering
• Patent Analysis

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Technology
• Takeaways
• Diagnostic Technologies
• Therapeutic Technologies
• Renal Replacement Technologies
• Market Breakdown by Pharmaceutical Drugs
• Takeaways
• Market Breakdown by End User
• Takeaways
• Geographic Breakdown
• Market Breakdown by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Competitive Analysis
• Strategic Analysis
• Investment Landscape

Chapter 8 Sustainability in the Chronic Kidney Disease Market: ESG Perspective

• Overview
• Sustainability Trends and Initiatives of AI in the Chronic Kidney Disease Industry
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Abbreviations
• References
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTELLAS PHARMA INC.
• BAXTER
• BAYER AG
• B. BRAUN SE
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• FRESENIUS MEDICAL CARE AG
• JOHNSON & JOHNSON
• LILLY USA LLC
• NOVARTIS AG
• PFIZER INC.
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• TORAY INDUSTRIES INC.
• Emerging Startups/Market Disruptors

List of Tables

• Summary Table : Global Market for Chronic Kidney Disease, by Region, Through 2030
• Table 1 : U.S. Regulatory Pathways for Chronic Kidney Disease Market
• Table 2 : European Regulatory Pathways for Chronic Kidney Disease Market
• Table 3 : Global Regulatory Summary for Chronic Kidney Disease Market
• Table 4 : Global Market for Chronic Kidney Diseases, by Technology, Through 2030
• Table 5 : Global Market for Chronic Kidney Diseases, by Diagnostic Technology, Through 2030
• Table 6 : Global Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
• Table 7 : Global Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 8 : Global Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 9 : Global Market for Chronic Kidney Disease, by End User, Through 2030
• Table 10 : Global Market for Chronic Kidney Disease, by Region, Through 2030
• Table 11 : North American Market for Chronic Kidney Disease, by Technology, Through 2030
• Table 12 : North American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
• Table 13 : North American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
• Table 14 : North American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 15 : North American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 16 : North American Market for Chronic Kidney Disease, by End User, Through 2030
• Table 17 : North American Market for Chronic Kidney Disease, by Country, Through 2030
• Table 18 : European Market for Chronic Kidney Disease, by Technology, Through 2030
• Table 19 : European Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
• Table 20 : European Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
• Table 21 : European Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 22 : European Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 23 : European Market for Chronic Kidney Diseases, by End User, Through 2030
• Table 24 : European Market for Chronic Kidney Disease, by Country, Through 2030
• Table 25 : Asia-Pacific Market for Chronic Kidney Disease, by Technology, Through 2030
• Table 26 : Asia-Pacific Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
• Table 27 : Asia-Pacific Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
• Table 28 : Asia-Pacific Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 29 : Asia-Pacific Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 30 : Asia-Pacific Market for Chronic Kidney Disease, by End User, Through 2030
• Table 31 : Asia-Pacific Market for Chronic Kidney Disease, by Country, Through 2030
• Table 32 : MEA Market for Chronic Kidney Disease, by Technology, Through 2030
• Table 33 : MEA Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
• Table 34 : MEA Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
• Table 35 : MEA Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 36 : MEA Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 37 : MEA Market for Chronic Kidney Disease, by End User, Through 2030
• Table 38 : MEA Market for Chronic Kidney Disease, by Country, Through 2030
• Table 39 : South American Market for Chronic Kidney Disease, by Technology, Through 2030
• Table 40 : South American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
• Table 41 : South American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
• Table 42 : South American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
• Table 43 : South American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
• Table 44 : South American Market for Chronic Kidney Disease, by End User, Through 2030
• Table 45 : South American Market for Chronic Kidney Disease, by Country, Through 2030
• Table 46 : Agreements, Collaborations, and Partnerships in the Chronic Kidney Diseases Market, 2023-2025
• Table 47 : ESG Risk Rankings for Chronic Kidney Disease Market, 2025*
• Table 48 : Abbreviations Used in this Report
• Table 49 : AbbVie Inc.: Company Snapshot
• Table 50 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 51 : AbbVie Inc.: Product Portfolio
• Table 52 : AbbVie Inc.: News/Key Developments, 2023-2025
• Table 53 : Amgen Inc.: Company Snapshot
• Table 54 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 55 : Amgen Inc.: Product Portfolio
• Table 56 : Amgen Inc.: News/Key Developments, 2023-2025
• Table 57 : Astellas Pharma Inc.: Company Snapshot
• Table 58 : Astellas Pharma Inc.: Financial Performance, FY 2023 and 2024
• Table 59 : Astellas Pharma Inc.: Product Portfolio
• Table 60 : Baxter: Company Snapshot
• Table 61 : Baxter: Financial Performance, FY 2023 and 2024
• Table 62 : Baxter: Product Portfolio
• Table 63 : Baxter: News/Key Developments, 2024 and 2025
• Table 64 : Bayer AG: Company Snapshot
• Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 66 : Bayer AG: Product Portfolio
• Table 67 : B. Braun SE: Company Snapshot
• Table 68 : B. Braun SE: Financial Performance, FY 2023 and 2024
• Table 69 : B. Braun SE: Product Portfolio
• Table 70 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 71 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 72 : Boehringer Ingelheim International GmbH: News/Key Developments, 2023-2024
• Table 73 : Fresenius Medical Care AG: Company Snapshot
• Table 74 : Fresenius Medical Care AG: Financial Performance, FY 2023 and 2024
• Table 75 : Fresenius Medical Care AG: Product Portfolio
• Table 76 : Fresenius Medical Care AG: News/Key Developments, 2024 and 2025
• Table 77 : Johnson & Johnson: Company Snapshot
• Table 78 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 79 : Johnson & Johnson: Product Portfolio
• Table 80 : Lilly USA LLC: Company Snapshot
• Table 81 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
• Table 82 : Lilly USA LLC: Product Portfolio
• Table 83 : Novartis AG: Company Snapshot
• Table 84 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 85 : Novartis AG: Product Portfolio
• Table 86 : Pfizer Inc.: Company Snapshot
• Table 87 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 88 : Pfizer Inc.: Product Portfolio
• Table 89 : Pfizer Inc.: News/Key Developments, 2025
• Table 90 : Siemens Healthineers AG: Company Snapshot
• Table 91 : Siemens Healthineers AG: Financial Performance, FY 2024 and 2025
• Table 92 : Siemens Healthineers AG: Product Portfolio
• Table 93 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 94 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 95 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 96 : Toray Industries Inc.: Company Snapshot
• Table 97 : Toray Industries Inc.: Financial Performance, FY 2023 and 2024
• Table 98 : Toray Industries Inc.: Product Portfolio
• Table 99 : List of a Few Emerging Startups in the Global Chronic Kidney Disease Market

List of Figures

• Summary Figure : Global Market Shares for Chronic Kidney Disease, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis: Chronic Kidney Disease Market
• Figure 2 : Market Dynamics of Chronic Kidney Disease
• Figure 3 : Patent Shares for Chronic Kidney Disease Market, by Jurisdiction, 2025
• Figure 4 : Global Market Shares for Chronic Kidney Diseases, by Technology, 2024
• Figure 5 : Global Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
• Figure 6 : Global Market Shares for Chronic Kidney Diseases, by Therapeutic Technology, 2024
• Figure 7 : Global Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 8 : Global Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 9 : Global Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 10 : Global Market Shares for Chronic Kidney Disease, by Region, 2024
• Figure 11 : North American Market Shares for Chronic Kidney Disease, by Technology, 2024
• Figure 12 : North American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
• Figure 13 : North American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
• Figure 14 : North American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 15 : North American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 16 : North American Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 17 : North American Market Shares for Chronic Kidney Disease, by Country, 2024
• Figure 18 : European Market Shares for Chronic Kidney Disease, by Technology, 2024
• Figure 19 : European Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
• Figure 20 : European Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
• Figure 21 : European Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 22 : European Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 23 : European Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 24 : European Market Shares for Chronic Kidney Disease, by Country, 2024
• Figure 25 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Technology, 2024
• Figure 26 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
• Figure 27 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
• Figure 28 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 29 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 30 : Asia-Pacific Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 31 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Country, 2024
• Figure 32 : MEA Market Shares for Chronic Kidney Diseases, by Technology, 2024
• Figure 33 : MEA Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
• Figure 34 : MEA Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
• Figure 35 : MEA Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 36 : MEA Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 37 : MEA Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 38 : MEA Market Shares for Chronic Kidney Disease, by Country, 2024
• Figure 39 : South American Market Shares for Chronic Kidney Disease, by Technology, 2024
• Figure 40 : South American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
• Figure 41 : South American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
• Figure 42 : South American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
• Figure 43 : South American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
• Figure 44 : South American Market Shares for Chronic Kidney Disease, by End User, 2024
• Figure 45 : South American Market Shares for Chronic Kidney Disease, by Country, 2024
• Figure 46 : Global Market Shares for Chronic Kidney Diseases, by Leading Companies, 2024
• Figure 47 : AbbVie Inc: Revenue Share, by Country/Region, FY 2024
• Figure 48 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 49 : Astellas Pharma Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 50 : Astellas Pharma Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 51 : BAXTER: Revenue Share, by Business Unit, FY 2024
• Figure 52 : BAXTER: Revenue Share, by Country/Region, FY 2024
• Figure 53 : Bayer AG: Revenue Share, by Business Unit, FY 2024
• Figure 54 : Bayer AG: Revenue Share, by Country/Region, FY 2024
• Figure 55 : B. Braun SE: Revenue Share, by Business Unit, FY 2024
• Figure 56 : B. Braun SE: Revenue Share, by Country/Region, FY 2024
• Figure 57 : Fresenius Medical Care AG: Revenue Share, by Business Unit, FY 2024
• Figure 58 : Fresenius Medical Care AG: Revenue Share, by Country/Region, FY 2024
• Figure 59 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
• Figure 60 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
• Figure 61 : Lilly USA LLC: Revenue Share, by Country/Region, FY 2024
• Figure 62 : Novartis AG: Revenue Share, by Business Unit, FY 2024
• Figure 63 : Novartis AG: Revenue Share, by Country/Region, FY 2024
• Figure 64 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 65 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 66 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2025
• Figure 67 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2025
• Figure 68 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 69 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 70 : Toray Industries Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 71 : Toray Industries Inc.: Revenue Share, by Country/Region, FY 2024